BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3111046)

  • 21. Alternating chemotherapy regimens for patients with metastatic breast cancer. A pilot study based on tumor marker kinetics. Cancer and Leukemia Group B.
    Kiang DT; Kennedy BJ; Younger J; Perry MC; Schilling A; Korzun AH; Nowak BS; Wood W
    Cancer; 1995 Feb; 75(3):826-30. PubMed ID: 7828133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type.
    Hasbini A; Mahjoubi R; Fandi A; Chouaki N; Taamma A; Lianes P; Cortès-Funes H; Alonso S; Armand JP; Cvitkovic E; Raymond E
    Ann Oncol; 1999 Apr; 10(4):421-5. PubMed ID: 10370784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5-fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study.
    Kolarić K; Vukas D; Potrebica V
    Tumori; 1989 Apr; 75(2):132-6. PubMed ID: 2741218
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma. A phase II randomized trial of the Italian Oncology Group for Clinical Research.
    De Lisi V; Cocconi G; Angelini F; Cavicchi F; Di Costanzo F; Gilli G; Rodinò C; Soldani M; Tonato M; Finardi C
    Cancer; 1996 Jan; 77(2):245-50. PubMed ID: 8625230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
    Alonso MC; Tabernero JM; Ojeda B; Llanos M; Solà C; Climent MA; Seguí MA; López JJ
    Breast Cancer Res Treat; 1995 Apr; 34(1):15-24. PubMed ID: 7749156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Three-drug combination chemotherapy for advanced urothelial tract carcinoma.
    Ohshima S; Ono Y; Fujita T; Aso Y
    Cancer Chemother Pharmacol; 1987; 20 Suppl():S20-3. PubMed ID: 2444354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results.
    Pacini P; Rinaldini M; Algeri R; Guarneri A; Tucci E; Barsanti G; Neri B; Bastiani P; Marzano S; Fallai C
    Eur J Cancer; 2000 May; 36(8):966-75. PubMed ID: 10885599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensive sequential chemotherapy with bleomycin, Oncovin, mitomycin C, and methotrexate followed by adriamycin, cisplatin, and cyclosphosphamide in squamous cell cancer of the head and neck.
    Wheeler RH; Baker SR; Liepman MK; Ensminger WD
    Med Pediatr Oncol; 1983; 11(1):12-9. PubMed ID: 6188032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II evaluation of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) in advanced, measurable breast carcinoma.
    Langer CJ; Catalano R; Weiner LM; Scher R; Bagchi P; Saren B; Comis RL
    Cancer Invest; 1995; 13(2):150-9. PubMed ID: 7874568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mitomycin C, melphalan and methotrexate combination chemotherapy for palliation of disseminated breast cancer.
    Perez DJ; Powles TJ; Gazet JC; Ford HT; Coombes RC
    Cancer Chemother Pharmacol; 1984; 13(1):36-8. PubMed ID: 6203662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
    Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
    J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adriamycin (doxorubicin), vinblastine, and mitomycin C combination chemotherapy in refractory breast carcinoma.
    Luikart SD; Witman GB; Portlock CS
    Cancer; 1984 Oct; 54(7):1252-5. PubMed ID: 6467151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes.
    Moliterni A; Bonadonna G; Valagussa P; Ferrari L; Zambetti M
    J Clin Oncol; 1991 Jul; 9(7):1124-30. PubMed ID: 2045854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.
    Ferreira Filho AF; Crown J; Cardoso F; Nogaret JM; Duffy K; Dolci S; Rowan S; O'Higgins N; Batter V; Paesmans M; Piccart MJ; Di Leo A
    Anticancer Res; 2002; 22(4):2471-6. PubMed ID: 12174946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
    Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Combination chemotherapy with mitomycin C, methotrexate, and vincristine (MMV) for metastatic breast cancer refractory to adriamycin].
    Nomura Y; Kanda K; Tashiro H; Hamada Y; Saeki K
    Gan To Kagaku Ryoho; 1983 Mar; 10(3):824-8. PubMed ID: 6411002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination chemotherapy with 5-fluorouracil, oral Idarubicin, and cyclophosphamide (FIC) in metastatic breast cancer--an open phase II study.
    Kolarić K; Potrebica V; Vukas D; Mechl Z; Sopkova B
    J Cancer Res Clin Oncol; 1988; 114(3):301-5. PubMed ID: 3164312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [5-Fluorouracil, adriamycin, and mitomycin C (FAM) combination chemotherapy in adenocarcinoma of the parotid gland].
    Inoue K; Horikoshi N; Mukaiyama T; Ogawa M; Kuraishi Y
    Gan No Rinsho; 1989 Mar; 35(4):481-5. PubMed ID: 2654442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The management of locally advanced breast cancer: a combined modality approach.
    Kantarjian HM; Hortobagyi GN; Smith TL; Blumenschein GR; Montague E; Buzdar AU; Martin RG
    Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1353-61. PubMed ID: 6548710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.